Cover Image
市場調查報告書

鞘氨醇-1-磷酸受体1:開發中產品分析

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 386362
出版日期 內容資訊 英文 90 Pages
訂單完成後即時交付
價格
Back to Top
鞘氨醇-1-磷酸受体1:開發中產品分析 Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Pipeline Review, H1 2018
出版日期: 2018年02月20日 內容資訊: 英文 90 Pages
簡介

本報告提供以鞘氨醇-1-磷酸受体1為目標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括了最新的新聞與發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

鞘氨醇-1-磷酸受体1概要

治療藥的開發

  • 開發中的產品 - 各開發階段
  • 開發中的產品 - 各治療範圍
  • 開發中的產品 - 各適應症

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Actelion Ltd
  • Arena Pharmaceuticals, Inc.
  • AstraZeneca Plc
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • GlaxoSmithKline Plc
  • Novartis AG

藥物簡介

暫停中的計劃

主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1303TDB

Summary:

According to the recently published report 'Sphingosine 1-Phosphate Receptor 1 - Pipeline Review, H1 2018'; Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) pipeline Target constitutes close to 20 molecules. Out of which approximately 20 molecules are developed by Companies.

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Sphingosine-1-phosphate receptor 1 (S1P receptor 1 or S1P1) is a G-protein coupled receptor. Signaling leads to the activation of RAC1, SRC, PTK2/FAK1 and MAP kinases. It plays an important role in cell migration, migration of osteoclast precursor cells, the regulation of bone mineralization and bone homeostasis and in the protection against ventilator-induced lung injury.

It is required for normal chemotaxis toward sphingosine 1-phosphate, normal embryonic heart development and normal cardiac morphogenesis. It inhibits sprouting angiogenesis to prevent excessive sprouting during blood vessel development.

The report 'Sphingosine 1-Phosphate Receptor 1 - Pipeline Review, H1 2018' outlays comprehensive information on the Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 3, 5, 8 and 1 respectively. Report covers products from therapy areas Immunology, Central Nervous System, Gastrointestinal, Cardiovascular, Dermatology, Musculoskeletal Disorders and Oncology which include indications Multiple Sclerosis, Ulcerative Colitis, Autoimmune Disorders, Rheumatoid Arthritis, Psoriasis, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Arthritis, Atopic Dermatitis, Cardiovascular Disease, Cerebral Aneurysms, Colitis, Crohn's Disease (Regional Enteritis), Dermatological Disorders, Dermatomyositis, Graft Versus Host Disease (GVHD), Inflammation, Inflammatory Bowel Disease, Kidney Transplant Rejection, Primary Biliary Cirrhosis, Relapsing Multiple Sclerosis (RMS), Stroke and Systemic Lupus Erythematosus.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1)
  • The report reviews Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Overview
    • Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Companies Involved in Therapeutics Development
    • Actelion Pharmaceuticals Ltd
    • Arena Pharmaceuticals Inc
    • Astellas Pharma Inc
    • AstraZeneca Plc
    • Boston Pharmaceuticals Inc
    • Bristol-Myers Squibb Co
    • Celgene Corp
    • GlaxoSmithKline Plc
    • Idorsia Ltd
    • LG Chem Ltd
    • Novartis AG
    • Sanofi
    • Sun Pharma Advanced Research Company Ltd
  • Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Drug Profiles
    • AKP-11 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-0028 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-4058 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-986104 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BOS-173717 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CBP-307 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cenerimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CP-9531 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etrasimod arginine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FP-253 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LC-510255 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NIBR-0213 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ozanimod hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ponesimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-247799 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SCD-044 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • siponimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize S1P1 for Multiple Sclerosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize S1P1 for Multiple Sclerosis and Rheumatoid Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize Sphingosine 1 Phosphate Receptor 1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Dormant Products
  • Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Discontinued Products
  • Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Product Development Milestones
    • Featured News & Press Releases
      • Jan 22, 2018: Arena Pharmaceuticals to Host Key Opinion Leader Event on S1P Modulation and Etrasimod in Autoimmune Diseases on January 29 in New York City
      • Nov 10, 2017: Arena Pharmaceuticals Completes Full Enrollment in Etrasimod Phase 2 Clinical Study for Ulcerative Colitis
      • Nov 09, 2017: Ozanimod Successful in Clinical Trials for Multiple Sclerosis
      • Oct 28, 2017: Efficacy and Safety Results from Second Phase III Trial (RADIANCE Part B) of Oral Ozanimod Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting
      • Oct 27, 2017: Efficacy and Safety Results from First Phase III Trial of Oral Ozanimod (SUNBEAM) Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting
      • Oct 25, 2017: Novartis Presents New Data on Siponimod at ECTRIMS
      • Oct 19, 2017: Phase III Efficacy and Safety Data for Oral Ozanimod in Relapsing Multiple Sclerosis to Be Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting
      • Oct 16, 2017: Results from Phase 2 Studies of Oral Ozanimod in Crohn's Disease and Ulcerative Colitis to Be Presented at World Congress of Gastroenterology at ACG2017
      • May 22, 2017: Celgene Announces Positive Results from RADIANCE, the Second Pivotal Phase III Trial of Oral Ozanimod in Patients with Relapsing Multiple Sclerosis
      • Apr 17, 2017: Arena Pharmaceuticals Announces Multiple Presentations at ASPET 2017 at Experimental Biology
      • Feb 21, 2017: TSRI-invented compound ozanimod shows positive results in late-stage clinical trial for relapsing multiple sclerosis
      • Feb 17, 2017: Celgene Announces Positive Results from Phase III SUNBEAM Trial of Oral Ozanimod in Patients with Relapsing Multiple Sclerosis
      • Feb 09, 2017: Arena Pharmaceuticals Announces Three Upcoming Presentations at the 12th Congress of European Crohn's and Colitis Organisation - Inflammatory Bowel Diseases 2017
      • Oct 17, 2016: Oral Ozanimod Efficacy and Safety Results from Phase 2 TOUCHSTONE Extension Trial in Patients with Ulcerative Colitis to Be Presented at UEGW and ACG
      • Oct 13, 2016: Celgene to Present New Data on Ozanimod at UEGW and ACG Congresses
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indications, H1 2018
  • Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by Actelion Pharmaceuticals Ltd, H1 2018
  • Pipeline by Arena Pharmaceuticals Inc, H1 2018
  • Pipeline by Astellas Pharma Inc, H1 2018
  • Pipeline by AstraZeneca Plc, H1 2018
  • Pipeline by Boston Pharmaceuticals Inc, H1 2018
  • Pipeline by Bristol-Myers Squibb Co, H1 2018
  • Pipeline by Celgene Corp, H1 2018
  • Pipeline by GlaxoSmithKline Plc, H1 2018
  • Pipeline by Idorsia Ltd, H1 2018
  • Pipeline by LG Chem Ltd, H1 2018
  • Pipeline by Novartis AG, H1 2018
  • Pipeline by Sanofi, H1 2018
  • Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2018
  • Dormant Products, H1 2018
  • Dormant Products, H1 2018 (Contd..1), H1 2018
  • Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Top 10 Indications, H1 2018
  • Number of Products by Mechanism of Actions, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
Back to Top